


9 BC	8 (B	3		÷			÷		3				N.			i.	(W)	ŝ		ŝ.		Ŕ	9	1	M	*	Ŵ	Ċ.		×.	ŝ.		8	9		8		Ű.
.		w.	5000	-	36) -	47	34 -	76	÷.	/(6)	<i>¥</i>	36	97	367	10	ġ.	300	34	767	÷	181	ĸ	(147)	×.	<i>3</i>	240	4	1967	8	(8)	36. -	$(\hat{\Phi})^{(1)}$	¥.	38	240	14	163	10
Disc	lair	\mathbf{n}	er	×.	÷.	÷,	ý.	1	5			(#)	11 10 10	je.	÷	Ű.		×.		X	÷.	×	200 2007 (÷	(4				8		÷.	98	11 10	3		8	сйу М	×.


This presentation is issued by L&T Technology Services Limited (the "**Company**") for general information purposes only, without regard to specific objectives, suitability, financial situations and needs of any particular person. This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment whatsoever. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person.

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. This presentation should not be relied upon as a recommendation or forecast by the Company. Please note that the past performance of the Company is not, and should not be considered as, indicative of future results. The Company cannot guarantee that these assumptions and expectations are accurate or will be realised. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements. The Company does not undertake to revise any forward-looking statement that may be made from time to time by or on behalf of the Company. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements.


This presentation may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of applicable laws.


The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation shall be relied upon as a promise or representation. The Company undertakes no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.






...Allows us to be the End-End Engineering Partner for our Clients








Our Six Strategic Growth Areas...







02 MedTech \$200 Bn by 2025E



03 5G \$155 Bn by 2025E



BIG BETS














Strategy for Profitable, Sustainable & Inclusive Growth

89 R&D **INNOVATION** LABS

Supporting focused investment areas





IoT solutions come to life- from connected workers to predictive analytics and industrial cybersecurity

Electric vehicle lab



Innovation design center for detailed engineering & testing on advanced electrical instruments

Smart manufacturing lab



Focused on engineering solutions for manufacturing operations management



Life science & diagnostic devices are validated using chemicals, drugs and bio-matter.

5G lab



Focused on for 5G development, NFV Benchmarking, Validation and Design services

Environment facility



Pre-compliance activities to test products under different environmental conditions.



Technology



Industry specific labs



Compliance testing labs



Enabling Innovation With World Class Solutions



eVOLTTS

In-house developed end-to-end vehicle electrification platform enabling faster GTM



Chest rAI[™]

Al-based chest X-ray analysis system to assist the radiologists in improving speed and accuracy of the diagnosis



Energy Management

Resulting to energy intensity reduction by 10-15% across multiple sites



Optical Subsystem

New age flow cytometer with high precision levels for single-cell population characterization





5G Enterprise

Best in-class lab for automation of 5G SA and NSA System and Testing test cases



Unmanned Aerial Vehicle

Enhanced Flight Control Computer and Structure Design

Creating Customer Value Via Crosspoll!nnovation

By bringing transformative ideas from other industries, LTTS' Innovations helped us reduce lead time to market.



5G TCU Testing from our Hi-Tech Segment for a Transportation Customer







Battery operated Autonomous Welding Robot from Industrial Products for a Plant Engineering manufacturer




Annotation Technology from Transportation being used for Imaging Medical Radiology





What Sets us Apart

Our Key Differentiators




Has Led Us To Where We Are



#1 Pure-Play Engineering Services Provider for two consecutive years



Leading Edge in Emerging **Tech Areas**




Digital Engineering	÷.	<u>)</u>	<u>1997</u>	(ij) 1	9	- 81	ă,		8	90	9.		÷.	3	A	\eros	space
Among Top 5 ESPs	085	9)	081)	97	18	.(#1)	.#	0.81	э.	181	8	(#))'	Amo	ng To	op 5 I	ER&D	players
	3	ě.)#`	1	ġ.		3		8	(96)	8		ŝ		1	1	
ADAS ADAS	047	ж.	(#11)	к;	19	-(4)	×.	.30	2	[38-7	×.	903	11 ⁻	A	uto	1	<u></u>
ADAS Among Top 3 E	SPs	ę	÷	Ē	9		X			Amon	g Top	5 4 i	n cor	npet	ency		<u>r</u>
	(96)	ж.	141	8.)		(181)	3	(40)	30	340	ф.	(0)	¢'.	19	(4)		
	(iii)	8	æ	÷.	3		÷	1	¥.		÷.		ŝ.	ą.	- 98		
Digital 📈	Thre	ad	98 C	i.	Di	00	-	(9)	и	(M)	¥0	N	/led	ical		᠂ᠰᡛ	~
Among To	p 3 ES	SPs		iii M	() ()	() (1) (1) (1)	- 	Amo	ng tł	ne Top	2 in	cor	npet	ency		J.	Ţ
	2 <u>14</u> 11	×.	(W)	-		- 140	-16 -	/#)	2	781	2	121	¥.		12		
IoT	1917 1917	Ŕ	ŵ:	ť	ű.	2	Ä		<u>.</u> / .	ж.	8		T	elec	om	1	GGA)
Among Top 4 E	SPs	ii.	2007	80	19	- M-	1		-M	06	Am	ong	the	Top 4	I ESP		AI
	99). 1	11 11 11	(6-c)	÷.			9				R.	36	8			2	
AI Engineering	98.0	ж. Ж	1877	¥.	78		ж		¥	263	¥.	161	8	18	(*)	Indu	strial
Among Top 5 ESPs		8			9		9	(#)	1		8		Mai	ntair	ned T	ор 2 р	osition

Leading Edge in Vertical Positioning



AP)

Transportation: Co-creating The Next-generation Of Mobility



Revenue: USD310mn+

(Q1FY23 annualized)

An automotive engineering service provider with strong expertise across the value chain, strong innovation credentials and a solid presence in the off-highway vehicle segment.

> -HfS Research, **Automotive Engineering Services Blueprint**

Automotive practice rated in Winner **Circle by HfS Research**




Off-highway practice rated as the Leading ESP for 5 consecutive year by Zinnov Management Consulting.



10+ State-of-the-art labs across Infotainment, ADAS/ Autonomous drive, Electric vehicles, EMI/EMC, Smart Manufacturing, Design & Tear Down.

Telecom & Hi-Tech: Strengthening Connectivity



Entertainment

L&T Technology Services | www.LTTS.com

Revenue: USD190mn+ (Q1FY23 annualized)

LTTS stood out for clients' very positive impressions of its operations and service delivery. Reference clients have praised LTTS's capability for design to manufacturing solutions

-HfS Research, **Embedded & Semicon Engineering Services Blueprint**

Rated as one of the leading global ESPs in embedded space by Zinnov Management Consulting




Rated among the top 5 embedded & semicon ESPs globally by HfS Research



Electronics

20+ partnerships and 40+ in-house solutions, IPs and accelerators.

Industrial Products: Infusing Technologies



Revenue: USD180mn+

(Q1FY23 annualized)

L&T Technology Services' deep multivertical expertise, rich IP portfolio such as UBIQWeise[™], iBEMS, W.A.G.E.S and innovation focused multi-domain labs gives it a clear advantage over its peers.

> -Zinnov Management Consulting, Zinnov Zones 2017 for IoT Technology Services

Rated as #1 engineering services company for the last 7 years by multiple industry experts




Rated in the Winner Circle by HfS Research for deep domain capabilities in IIoT



20+ labs and over 150+ authored/ co-authored patents

Plant Engineering: Extending Industry 4.0



Revenue: USD150mn+

(Q1FY23 annualized)

L&T Technology Services' deep understanding of Plant Engineering and track record of making products and manufacturing smarter, established it in the Winners Circle.

> -HfS Research, Industry 4.0 Services Blueprint Assessment


Rated in the Winner's Circle by HfS Research in their Industry 4.0 Blueprint



Extensive global reach and expertise with geographically distributed resource base working across 200+ global manufacturing locations



Medical Devices: Touching Lives



Revenue: USD110mn+

(Q1FY23 annualized)

The ability to pro-actively build and demonstrate proof-of-concepts, take risks, and explore new ways of doing things has created stellar results for our partnership with LTTS.

> - Leading American Medical Devices & Lifesciences conglomerate


Rated as one of the leading global ESPs for Medical devices for the past 3 years consecutively

Innovation focused culture with 50+ patents to credit

5

cGMP focused manufacturing practice

Diversified Business Mix



	Top C	lients	Contri	butio	on i		i de la del	Scale-up of
60% -	% o f	f Revei	nue (LTN	/I)	54%			Customer Revenue (USD Mn)
50% - 40% -			43%		a 2 2			30 Million +
30% -	28%				* * *	10 A	* *	20 Million +
20% -		e e Konstanti Konstanti			* •		· · · · · · · · · · · · · · · · · · ·	10 Million +
10% -					е И		ж. н (4) А	5 Million+
0%					a A	6 8		1 Million +

Scale-up of million dollar clients

Customer Revenue (USD Mn)	FY20	FY21	FY22	Q1 FY23
30 Million +	2	0	2	2
20 Million +	8	3	6	7
10 Million +	21	20	22	23
5 Million+	43	39	48	51
1 Million +	113	122	136	142

Performance Highlights

FY17	FY18	FY19	FY20	FY21	FY22	Parameters	Q1 FY23
484	580	723	786	737	880	Revenue from Operations (USD mn)	239.5
32,483	37,471	50,783	56,191	54,497	65,697	Revenue from Operations (INR mn)	18,737
16.1%	13.0%	16.0%	16.5%	14.5%	18.3%	EBIT Margin	18.3%
4,249	5,060	7,656	8,186	6,633	9,570	Net Income (INR mn)	2,742
13.1%	13.5%	15.1%	14.6%	12.2%	14.6%	Net Income Margin	14.6%
42.1	49.6	74.1	78.6	63.3	90.9	Earnings Per Share (INR)	26.0
7.0	16.0	21.0	21.0	22.0	35.0	Dividend Per Share (INR)	-

Financial Performance – Q1 FY23

Amount in ₹ million

Income Statement	Q1 FY22	Q4 FY22	Q1 FY23	QoQ	YoY
Revenue	15,184	17,561	18,737	6.7%	23.4%
Cost of sales	10,118	11,765	12,560		
Gross Profit	5,066	5,796	6,177	6.6%	21.9%
Selling, General & Administration Expenses	1,889	1,992	2,167		
EBITDA	3,177	3,804	4,010	5.4%	26.2%
Depreciation & Amortisation	554	530	576		
EBIT	2,623	3,274	3,434	4.9%	30.9%
Other Income, net	334	314	340		
Income tax expense	787	956	1,024		
Minority Interest	8	12	8		
Net Income	2,162	2,620	2,742	4.7%	26.9%
Margins (%)					
Gross Margin	33.4%	33.0%	33.0%		
EBITDA Margin	20.9%	21.7%	21.4%		
EBIT Margin	17.3%	18.6%	18.3%		
Net Income Margin	14.2%	14.9%	14.6%		
Earnings Per Share (INR)					
Basic	20.57	24.83	25.98		
Diluted	20.44	24.78	25.95		

Financial Performance – Q1 FY23

A		T	
1 mol	int ir	n z m	IIIIAn
Amou		1 \ 11	

the thet he they and the and they all the	itat na tati a tati	Amount in ₹ millio	on	1.461	3		E.		2	. 0	- 18	10		2	1.001	5. 2	1.00	Ą	۱mol	unt in	₹mi	illion
Balance Sheet	FY22	Q1 FY23	Cas	h Fl	ow	Sum	ima	ry							FY2	22			Y	rd Fi	<mark>(23</mark>	
Assets			Net	casł	n pro	vide	d by	oper	ating	g acti	vities	5			10,0)62				1,41	7	
Property and equipment	6,496	6,549	Сар	ex											-1,5	55				-503	3	
Intangible Assets and Goodwill	6,430	6,453	Free	e Cas	sh Flo	w									8,5	07				914		
Accounts Receivable	16,959	16,820	Free Cash Flow to Net Income (%)								89	%				33%						
Unbilled Revenues	2,610	4,411		0.40	4		90.		R)	2	.(#+	28	5.00	.0.	(#1	<u>8</u>	1851	2	:19	(1 8)	28	<u>195</u>
Investments	14,779	16,960	8	19) -	8	90) -	×.			<u>(8</u>		<u>(</u>)		100 100 100	8	Ш. Ц	(***	Ś)	98) -
Cash and Cash equivalents	6,742	5,449			Ж. 	(1947) 	10 10	(4.)	*	19 20	()#() 	(# 	- 443	.# 	045 	¥.	08.2	*E	3#) #1 	() ()	
Other current assets	3,022	2,609			* *		8) 6)	187	8 	10							283 24.7	10 10				2,85
Other non-current assets	3,872	2,890			i.		- 		-			i i i i i i i i i i i i i i i i i i i		- X		4						
Total Assets	60,910	62,141		- 1961	11	246	×.	78°)	ŵ.	28	2.945	Эř	- 1963	x	(#1)	Ψ.	-	÷	: is	996	34	*
Liabilities and Shareholders' Equity)e	ŝ.		9	3 8		3		1	(*)	ž	,#Ì	×.		ŝ		:(#)	(in	СŶу.
Shareholders' Funds	41,625	44,054		/#)	Ŷ	781.	£	087	15	34	092	38	197	÷	281	Эř	240	*	78	- 191	18	- 67
Other current liabilities	13,789	13,285	×.		ž.		8	(11) (91)	al an	8		8	1	1	98) 1981	8		φ.		29) 1	<u>(</u> e	
Other non-current liabilities	5,359	4,656			- Mi - 17	048	8		10	18 20		94. 195	542 1	*		*	36	83 54	18		96	(140)
Minority Interest	137	146			×			1943	10	19 14	1号。 (金)			×		el R		10 11				
Total Liabilities	60,910	62,141							22													

Remote Health Monitoring Application

WHAT WE ENABLED

- Design, development, testing and validation (formal & informal) of secure Class II medical solution for Remote Home Monitoring of Medication dosage and patient health
- Custom algorithm to identify trends and support HCPs in prescribing future possible medication; Option to notify patients on the future steps through the application
- Automation of multiple processes and document generation for better HCP experience

Secure self-medication and remote monitoring application for enhanced patient experience

OUR EXPERTISE

- Deep, end-to-end and proven expertise of Medical Devices Product development Value chain
- Deep expertise and understanding of standards such as IEC 62304, ISO 14971, etc. relevant to SaMD; ISO 13485 certified centers and QMS system
- Reusable assets and extensive ecosystem partnership

Next-gen connected cybersecure Surge Protection Monitoring Device

WHAT WE ENABLED

- End-to-end design and development of next-gen connected cyber-secured industrial surge protector with advanced features such as touchscreen-based GUI, multi-connectivity options
- Implemented innovative FPGA based design enabling faster detection of surges;
 Innovative DSP to enable accurate detection of power quality
- End-to-end design of firmware for precise measurement

Highly Modular design; Configurable into 6 different variants

OUR EXPERTISE

- Electric measurement and analytics domain a core differentiator
- Use of Power electronics, EMI/EMC and Surge labs
- Deep understanding of product cybersecurity and usage of Devsecops

Machine Health Monitoring through Embedded Al

WHAT WE ENABLED

- End to end use-case creation, design, development, testing of a portable multi-test machine health monitoring device used by service technician in pharma industry
- Development of custom Embedded AI application to analyze machine health and reporting at the device; Integration with existing and legacy display monitors

Plug and play multi-test portable machine health monitoring device

50% reduction in Service time

OUR EXPERTISE

- Deep, end-to-end and proven expertise in testing and measurement domain
- Proven Chip to cloud and Embedded AI expertise
- Reusable assets and extensive ecosystem partnership